TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Topical Nitric Oxide Trial in Chronic Non-Healing Wounds

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have a chronic (\> 8 weeks duration) colonized cutaneous ulcer (defined as a wound containing a local margin of erythema, edema or tenderness; presence of exudates; and/or presence of a malodorous smell)in their lower extremity (below the knee) resulting from either diabetes or venous stasis disease.~* Are 18 years of age or older.~Exclusion Criteria:~* Have had a change in their topical treatment during the last 4 weeks~* Have evidence of Clinical Infection~* Have a transcutaneous oxygen tension \<30mmHg~* Have evidence of the ulcer or infection extending to the underlying muscle or bone.~* Are pregnant.~* Are less than 18 years of age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Topically applied Nitric Oxide (Type: EXPERIMENTAL): Topically applied Nitric Oxide for 8 hours daily for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a history of chronic anemia defined as a documented Hb value of \<= 11.0 g/dL~* No active cancer~* At least 65 years of age with life expectancy of \> 6 months~* Community dwelling patients~* Patients with a Short Physical Performance (SPPB) Summary Score of 4-10 at screening and baseline~* Patients with a Mini Mental State Examination (MMSE) score \>= 24~Exclusion Criteria:~* Positive stool guaiac test~* Diagnosis of multiple myeloma and/or MGUS~* History of venous thromboembolytic disease~* Previous treatment with Epoetin alfa, Darbepoetin or any form of erythropoietin recently~* Uncontrolled or severe cardiovascular disease

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study in Patients Who Underwent an Haploidentical Transplantation With T-repleted Bone Marrow

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- patients affected by hematologic neoplasia who underwent a haploidentical transplantation (2-3 mismatches) from a familiar donor, with non-ex vivo manipulated bone marrow and post-transplantation cyclophosphamide~Exclusion Criteria:~* ex vivo manipulated bone marrow transplantation~* use of antilymphocyte serum during conditioning

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- transplanted patients (Type: None): T-repleted haploidentical transplanted patients in Italy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TXA and Corona Virus 2019 (COVID19) in Outpatients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Positive COVID-19 test~* Outpatient~* Age \>/= 19 y.o.~Exclusion Criteria:~* Allergic reaction to tranexamic acid~* History of hypercoagulation disorders (deep venous thrombosis, pulmonary thromboembolism)~* Ongoing anticoagulation~* History of GI bleeding~* History of Seizures~* Cardiac or other vascular stents~* History of severe renal disease~* History of intracranial hemorrhage

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tranexamic Acid Treatment (Type: EXPERIMENTAL): None
- Placebo Treatment (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: This Study is to Determine if Degenerative Spinal Pain and Disorders Cause the Levels of Substance P to Change in a Patients Saliva, Blood and/or Cerebrospinal Fluid.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Undergoing spinal surgery for medically refractory spinal radiculopathy,~* myelopathy or neurogenic claudication based on either history, physical examination or radiologic studies demonstrating neural compression or degenerative disc disease.~* Undergoing surgery for medically refractory axial spinal pain.~Exclusion Criteria:~* Previous spinal procedures or operations,~* radicular pain,~* history of fibromyalgia,~* chronic pain,~* rheumatoid arthritis,~* autoimmune disorders,~* HIV,~* PTSD,~* Major Depressive Disorder,~* migraine headaches or active rhinosinusitis,~* nicotine intake

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Healthy volunteers (Type: None): None
- surgery for spinal radiculopathy (Type: None): None
- surgery for axial spine pain (Type: None): None
- myelography for spinal pain (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study of GSK1605786A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previous participation in a GSK-sponsored study with GSK1605786A~* Written informed consent prior to any study-specific procedures~* Female subjects: To be eligible, females of child-bearing potential must be sexually inactive or commit to consistent and correct use of a contraceptive method of birth control with less than 1% failure rate~Exclusion Criteria:~* If female, is pregnant, has a positive pregnancy test or is breast-feeding, or is planning to become pregnant~* Subjects with known or suspected coeliac disease or a positive screening test for anti-tissue transglutaminase antibodies should have been excluded from enrolment into any induction study. Subjects in whom a diagnosis of coeliac disease is subsequently suspected should be tested for anti-tissue transglutaminase antibodies and excluded or withdrawn from the study upon positive test result~* Fixed symptomatic stenoses or strictures of small bowel or colon~* Enterocutaneous, abdominal or pelvic fistulae likely to require surgery during the study period~* Current sepsis or infections requiring intravenous antibiotic therapy greater than 2 weeks~* Evidence of hepatic dysfunction or viral hepatitis~* Subjects who have demonstrated safety or tolerability issues during participation in a previous study with GSK1605786A which, in the opinion of the investigator, was possibly related to study treatment and poses an unacceptable risk to the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK1605786A (Type: EXPERIMENTAL): 500 milligrams twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of the Contour Neurovascular SystemTM

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-80 years at screening~2. Unruptured saccular IA in the anterior or posterior circulation with dimensions consistent with Table 2~3. IA appears suitable for Contour Neurovascular SystemTM device Patient has the necessary mental capacity to participate and is willing and able to participate in the study for the duration of the study follow-up and is able to comply with study requirements Patient able to understand and sign a study-specific informed consent form~Exclusion Criteria:~1. Ruptured IA~2. Any other IA that requires treatment in the next year~3. IA width \>8.5 or \<2 mm~4. IA neck \>8 or \<2 mm~5. IA minimum height \<4mm~6. IA embolisation would most likely cause stroke~7. Target IA contains other devices/implants (e.g., coils)~8. Inability to access the target IA with the microcatheter~9. Any congenital or iatrogenic coagulopathy~10. Platelet count \<50,000/microliter~11. Known allergy to platinum, nickel or titanium~12. Known allergy to contrast agents~13. Stenosis of the target IA's parent vessel \>50%~14. Taking daily aspirin or other platelet inhibitor (clopidogrel or equivalent) other than for the target aneurysm~15. Taking any anticoagulants (e.g., warfarin)~16. Abnormal clotting parameters~17. Pregnant, breastfeeding or planning pregnancy in the next 2 years~18. Other medical conditions that could increase the risk of neurovascular procedures (e.g., liver failure, cancer, etc.) or ability to comply with study requirements Participating in another study with investigational devices or drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Contour Neurovascular System placement (Type: EXPERIMENTAL): Treatment of intracranial aneurysm with the Contour Neurovascular System device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with any NIH subtype of chronic GVHD that is being treated with ECP~* Karnofsky Performance Scale (KPS) \> 60% at time of study enrollment~* Life expectancy \> 3 months~* Steroid dose not greater than 2 mg/kg prednisone equivalent at time of study enrollment~* If patient has steroid refractory GVHD (defined as worsening of GVHD after 3 days of 2 mg/kg prednisone equivalent or no improvement after 7 days of 2 mg/kg prednisone equivalent), time interval from start of steroids to initiation of ECP should not be \> 14 days~* No use of an investigational agent within 2 weeks of starting ECP~* No uncontrolled bacterial, fungal or viral disease (therapy for cytomegalovirus \[CMV\] viremia is permitted)~* No evidence of relapse or progression of underlying disease (molecular evidence of relapse/progression or mixed chimerism is permitted)~* Women of childbearing potential (WOCBP) should be willing to use 2 forms of contraception; male patients should be willing to use contraception~* Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care~Exclusion Criteria:~* Female patients who are breastfeeding or pregnant~* Patients known to be human immunodeficiency virus (HIV) positive~* Bronchiolitis obliterans as the sole indication of ECP~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study~* Mechanical ventilation, renal replacement therapy, admitted in intensive care until at time of enrollment~* Stage 4 gastrointestinal GVHD as per Seattle-Glucksberg criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Treg predictor of response to ECP) (Type: EXPERIMENTAL): Patients undergo ECP twice a week for 4 weeks and then twice a week every 2 weeks for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin in the Prevention of Recurrent Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (\>=18) patients~2. At least 2 episodes of acute pancreatitis or acute flares of chronic pancreatitis~3. Written consent to participate in the study~Exclusion Criteria:~1. \<2 episodes of pancreatitis in the last 12 months.~2. Statin consumption in the previous year.~3. Contraindications to the use of Statins~4. Cholelithiasis or choledocholitiasis diagnosed in the last episode of pancreatitis~5. Endoscopic sphyncterotomy and/or cholecystectomy and/or pancreatic surgery between last episode of AP and recruitment or patients who are expected to undergo one of this techniques in less than a year.~6. Serum triglycerides \>500 mg/dL without previous specific treatment before the last episode of pancreatitis, or in patients expected to have a change in their specific hypertriglyceridemia treatment in less than 1 year~7. Primary hyperparathyroidism that has been operated between last episode of pancreatitis and recruitment or will be operated in less than 1 year~8. Iatrogenic Pancreatitis~9. Abstinence syndrome due to alcohol or drugs and/or delirium tremens in the last 6 months before recruitment~10. Previous (last year) failure to attend follow-up medical visits, social problems that may be associated to failure to take the medication or to perform an adequate follow-up~11. Pregnancy, breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo~1 year
- Simvastatin (Type: EXPERIMENTAL): 40 mg~1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Effectiveness of Different Doses of Chrysalin in Adults Who Have a Broken Wrist

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* An unstable and/or displaced fracture of the distal radius~* Fracture classified as primary intra-articular or extra-articular~* Male, or non-pregnant, non-lactating female at least 18 years old. If female of childbearing potential, must have confirmed negative pregnancy test prior to administration of study product. Must agree to use a medically approved method of birth control for 6 months.~* Need ability to understand study requirements, provide written informed consent, and comply with study protocol~* Need ability to understand and provide written authorization for use and disclosure of health information per Health Insurance Portability and Accountability Act (HIPAA)~Exclusion Criteria:~* History of distal radius fracture of the affected limb 2 years prior to study enrollment~* History of uncontrolled Type I or Type II diabetes mellitus~* History or clinical evidence of any active medical disease or condition which would make the subject, in the opinion of the investigator, unsuitable for the study, or could potentially confound the results of the study~* Concurrent use of other investigational (non-Food and Drug Administration \[FDA\]-approved) agent or device~* Participation in any other clinical study within 90 days prior to treatment with the study drug~* Female subjects who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 micrograms (Type: EXPERIMENTAL): None
- 30 micrograms (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- 3 micrograms (Type: EXPERIMENTAL): None
- 1 microgram (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Body Composition, Bone Health and Hormonal Status in HIV-1-infected Individuals

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented and confirmed HIV-1-infection~* Aged 18 years or above~* Naïve to anti-retroviral treatment, unless anti-retrovirals were taken in the context of occupational or non-occupational post-exposure prophylaxis or in the context of prevention of mother-to-child transmission~* Willingness to sign the written informed consent~Exclusion Criteria:~* Pregnancy and breastfeeding~* Patients receiving medical care through an 'emergency care package'

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria: The main inclusion criteria is listed below, additional inclusion criteria is in the protocol.~* Men or women 50 to 75 years of age. Women must be of non-childbearing potential. Sexually active men who are not surgically sterile must agree and commit to use of barrier contraception during the study and for at least 12 weeks after the last dose of PLA.~* Diagnosed with idiopathic OA of the knee for at least 3 months duration in accordance with \[1986\] American College of Rheumatology (ACR) clinical and radiographic criteria: knee pain, the presence of osteophytes, and any one of the following: age \>50 years, crepitus, or morning stiffness \<30 minutes.~* Radiographic confirmation of OA at the target joint (weight-bearing anteroposterior and lateral views) within 1 year of screening.~* Must be currently treated for OA with a stable daily dose of 1 NSAID, including COX-2 inhibitors, not exceeding the maximum recommended dose in the product label, and taken as prescribed by the physician, starting at least 4 weeks before the screening visit.~Exclusion Criteria: These are some of the main exclusion criteria for the the study. Additional exclusion are included in the protocol.~* History of or suspected current esophageal or gastrointestinal bleeding, ulcers, obstruction, or perforation, or pancreatitis.~* Grade 4 severity on the Kellgren-Lawrence Scale on the screening target knee radiograph.~* Any significant cardiovascular, hematologic, blood dyscrasia, endocrine, respiratory, neurologic, psychiatric, metabolic, immunologic, infectious, hepatic, or renal condition that the investigator considers detrimental to the subject's participating in the study or that may prevent the successful completion of the study.~* Any clinically significant laboratory abnormality.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Outcomes After Surgery for Necrotizing Soft Tissue Infections

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~all patients ≥ 18 years presenting with necrotizing soft tissue infections admitted to Westchester Medical Center, who will undergo surgical management~Exclusion Criteria:~Age \< 18 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues